文献速递心力衰竭与心肌病

低血浆转甲状腺素蛋白浓度与普通人群新发心力衰竭风险的关联

Association of Low Plasma Transthyretin Concentration With Risk of Heart Failure in the General Population.
PubMed 文献 · JAMA Cardiol · 2021-01-01

研究基于丹麦普通人群的两个前瞻性队列(CGPS n=9582,CCHS n=7385),评估低血浆转甲状腺素蛋白浓度与心衰发病风险的关系。结果显示,转甲状腺素蛋白浓度≤第5百分位者心衰风险升高(CGPS HR 1.6,95%CI 1.1-2.4;CCHS HR 1.4,95%CI 1.1-1.7),且男性风险最高;TTR基因型与转甲状腺素蛋白浓度降低及心衰风险呈阶梯式关联。

要点

  • 低血浆转甲状腺素蛋白浓度(≤第5百分位)与新发心衰风险升高相关。
  • 男性低转甲状腺素蛋白水平者心衰风险最高。
  • TTR基因型导致转甲状腺素蛋白浓度降低,且与心衰风险增加呈趋势关联。

核心结论

  • 较低的血浆转甲状腺素蛋白浓度及基因决定的低转甲状腺素蛋白浓度与较高的新发心衰风险相关,提示低转甲状腺素蛋白浓度作为四聚体不稳定标志物与普通人群新发心衰可能存在机制关联。

研究设计与样本

  • 研究纳入丹麦普通人群的两个相似前瞻性队列:哥本哈根普通人群研究(CGPS;n=9582)和哥本哈根城市心脏研究(CCHS;n=7385)。
  • CGPS数据收集于2003年11月至2017年3月,CCHS数据收集于1991年11月至1994年6月,两个队列的参与者均随访至2017年3月以观察生存终点。
  • 数据分析于2019年3月至6月进行。

主要发现

  • CGPS中位(IQR)随访12.6(12.3-12.9)年,441人(4.6%)发生心衰;CCHS中位(IQR)随访21.7(11.6-23.8)年,1122人(15.2%)发生心衰。
  • 基线血浆转甲状腺素蛋白浓度≤第5百分位与新发心衰相关:CGPS HR 1.6(95%CI 1.1-2.4),CCHS HR 1.4(95%CI 1.1-1.7)。
  • 低转甲状腺素蛋白水平者中心衰风险最高见于男性。
  • 与p.T139M(转甲状腺素蛋白稳定变异)相比,TTR基因型与转甲状腺素蛋白浓度阶梯式降低相关:野生型TTR -16.5%,p.G26S -18.1%,其他变异杂合子(p.V142I、p.H110N和p.D119N)-30.8%(趋势P<.001)。
  • 对应的新发心衰HR分别为1.14(95%CI 0.57-2.28)、1.29(95%CI 0.64-2.61)和2.04(95%CI 0.54-7.67)(趋势P=.04)。

关键数值与推荐

  • 转甲状腺素蛋白浓度暴露分组:≤第5百分位、第5至95百分位(参照)、>第95百分位。
  • 新发心衰通过丹麦国家患者登记处识别。

临床怎么用

  • 在普通人群中,低血浆转甲状腺素蛋白浓度可能提示心衰风险增加,尤其男性。
  • TTR基因型检测有助于识别转甲状腺素蛋白四聚体不稳定相关的心衰高风险个体。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Several lines of evidence support low plasma transthyretin concentration as an in vivo biomarker of transthyretin tetramer instability, a prerequisite for the development of both wild-type transthyretin cardiac amyloidosis (ATTRwt) and hereditary transthyretin cardiac amyloidosis (ATTRm). Both ATTRm and ATTRwt cardiac amyloidosis may manifest as heart failure (HF). However, whether low plasma transthyretin concentration confers increased risk of incident HF in the general population is unknown. OBJECTIVE: To evaluate whether low plasma transthyretin concentration is associated with incident HF in the general population. DESIGN, SETTING, AND PARTICIPANTS: This study included data from 2 similar prospective cohort studies of the Danish general population, the Copenhagen General Population Study (CGPS; n = 9582) and the Copenhagen City Heart Study (CCHS; n = 7385). Using these data, first, whether low concentration of plasma transthyretin was associated with increased risk of incident HF was tested. Second, whether genetic variants in TTR associated with increasing tetramer instability were associated with lower transthyretin concentration and with higher risk of HF was tested. Data were collected from November 2003 to March 2017 in the CGPS and from November 1991 to June 1994 in the CCHS; participants from both studies were observed for survival time end points until March 2017. Data were analyzed from March to June 2019. EXPOSURES: Transthyretin concentration at or below the 5th percentile, between the 5th and 95th percentile (reference), and greater than the 95th percentile; genetic variants in TTR. MAIN OUTCOME AND MEASURE: Incident HF identified using the Danish National Patient Registry. RESULTS: Of 9582 individuals in the CGPS, 5077 (53.0%) were women, and the median (interquartile range [IQR]) age was 56 (47-65) years. Of 7385 individuals in the CCHS, 4452 (60.3%) were women, and the median (IQR) age was 59 (46-70) years. During a median (IQR) follow-up of 12.6 (12.3-12.9) years and 21.7 (11.6-23.8) years, 441 individuals (4.6%) in the CGPS and 1122 individuals (15.2%) in the CCHS, respectively, developed HF. Baseline plasma transthyretin concentrations at or below the 5th percentile were associated with incident HF (CGPS: hazard ratio [HR], 1.6; 95% CI, 1.1-2.4; CCHS: HR, 1.4; 95% CI, 1.1-1.7). Risk of HF was highest in men with low transthyretin levels. Compared with p.T139M, a transthyretin-stabilizing variant, TTR genotype was associated with stepwise lower transthyretin concentrations for wild-type TTR (-16.5%), p.G26S (-18.1%), and heterozygotes for other variants (p.V142I, p.H110N, and p.D119N; -30.8%) (P for trend <.001). The corresponding HRs for incident HF were 1.14 (95% CI, 0.57-2.28), 1.29 (95% CI, 0.64-2.61), and 2.04 (95% CI, 0.54-7.67), respectively (P for trend = .04). CONCLUSIONS AND RELEVANCE: In this study, lower plasma and genetically determined transthyretin concentrations were associated with a higher risk of incident HF, suggesting a potential mechanistic association between low transthyretin concentration as a marker of tetramer instability and incident HF in the general population.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Greve AM, Christoffersen M, Frikke-Schmidt R, et al. Association of Low Plasma Transthyretin Concentration With Risk of Heart Failure in the General Population. JAMA Cardiol. 2021. PMID: 33237279. doi:10.1001/jamacardio.2020.5969

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。